Starkes Jahresergebnis: Novartis steigert den Nettoumsatz um 10%, das operative Kernergebnis um 18% (kWk¹) sowie die Margen. Weitere Innovationsdynamik mit mehreren positiven Phase-3-Ergebnissen
January 31, 2024 01:00 ET
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Geschäftsjahr (fortzuführende Geschäftsbereiche2)Der Nettoumsatz wuchs um +10% (kWk, +8% USD), und das operative Kernergebnis verbesserte sich um +18%...
Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
January 19, 2024 10:00 ET
|
Novartis Pharma AG
In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs. 8.5 months with high-dose octreotide LAR in patients with newly diagnosed grade 2...
Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia
January 08, 2024 01:15 ET
|
Novartis Pharma AG
MEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid...
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
January 05, 2024 09:23 ET
|
Novartis Pharma AG
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyondNew 70,000-square foot RLT facility is the...
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)
December 11, 2023 01:15 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1;...
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
December 10, 2023 19:30 ET
|
Novartis Pharma AG
APPLY-PNH extension data show that continuous Fabhalta® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to...
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
December 08, 2023 09:15 ET
|
Novartis Pharma AG
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in...
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
December 05, 2023 19:16 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement...
Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day
November 28, 2023 01:00 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR ‘Pure-play’ innovative medicines strategy focused on four therapeutic areas and five technology platforms, which offer potential for consistent growth ...
Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
November 20, 2023 01:15 ET
|
Novartis Pharma AG
Late-breaking final iDFS analysis from NATALEE investigating Kisqali® (ribociclib) in broad population of patients with stage II and III HR+/HER2- early breast cancer, including those with...